Atea Pharmaceuticals, Inc. Income Tax Expense
Atea Pharmaceuticals, Inc. (AVIR) reported Income Tax Expense of $24.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxExpenseBenefit · last filed 2026-08-12
- Atea Pharmaceuticals, Inc. income tax expense (benefit) for the quarter ending 2026-06-30 was $24.00K, a 88.41% decline year-over-year.
- Atea Pharmaceuticals, Inc. income tax expense (benefit) for the quarter ending 2026-03-31 was $50.00K, a 75.37% decline year-over-year.
- Atea Pharmaceuticals, Inc. income tax expense (benefit) for the quarter ending 2025-12-31 was -$6.77M, a 3108.00% decline year-over-year.
- Atea Pharmaceuticals, Inc. income tax expense (benefit) for the quarter ending 2025-09-30 was $196.00K, a 13.27% decline year-over-year.
- Atea Pharmaceuticals, Inc. income tax expense (benefit) for fiscal 2025 was -$6.16M, a 766.16% decline from fiscal 2024.
- Atea Pharmaceuticals, Inc. income tax expense (benefit) for fiscal 2024 was $925.00K, a 9.14% decline from fiscal 2023.
- Atea Pharmaceuticals, Inc. income tax expense (benefit) for fiscal 2023 was $1.02M.
- Atea Pharmaceuticals, Inc. income tax expense (benefit) for fiscal 2022 was -$3.59M, a 120.63% decline from fiscal 2021.
| Period end | Income Tax Expense (Benefit) 3 month | Income Tax Expense (Benefit) 6 month | Income Tax Expense (Benefit) 9 month | Income Tax Expense (Benefit) 12 month |
|---|---|---|---|---|
| 2026-06-30 | $24.00K 10-Q · filed 2026-08-12 | $74.00K 10-Q · filed 2026-08-12 | -$6.69M derived: sum of 3 quarters · filed 2026-08-12 | -$6.50M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $50.00K 10-Q · filed 2026-05-12 | -$6.72M derived: sum of 2 quarters · filed 2026-05-12 | -$6.52M derived: sum of 3 quarters · filed 2026-05-12 | -$6.32M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | -$6.77M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | -$6.57M derived: sum of 2 quarters · filed 2026-03-05 | -$6.37M derived: sum of 3 quarters · filed 2026-08-12 | -$6.16M 10-K · filed 2026-03-05 |
| 2025-09-30 | $196.00K 10-Q · filed 2025-11-12 | $403.00K derived: sum of 2 quarters · filed 2026-08-12 | $606.00K 10-Q · filed 2025-11-12 | $831.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $207.00K 10-Q · filed 2026-08-12 | $410.00K 10-Q · filed 2026-08-12 | $635.00K derived: sum of 3 quarters · filed 2026-08-12 | $861.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $203.00K 10-Q · filed 2026-05-12 | $428.00K derived: sum of 2 quarters · filed 2026-05-12 | $654.00K derived: sum of 3 quarters · filed 2026-05-12 | $897.00K derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $225.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $451.00K derived: sum of 2 quarters · filed 2026-03-05 | $694.00K derived: sum of 3 quarters · filed 2026-03-05 | $925.00K 10-K · filed 2026-03-05 |
| 2024-09-30 | $226.00K 10-Q · filed 2025-11-12 | $469.00K derived: sum of 2 quarters · filed 2025-11-12 | $700.00K 10-Q · filed 2025-11-12 | $1.05M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $243.00K 10-Q · filed 2025-08-07 | $474.00K 10-Q · filed 2025-08-07 | $823.00K derived: sum of 3 quarters · filed 2025-08-07 | $1.04M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $231.00K 10-Q · filed 2025-05-12 | $580.00K derived: sum of 2 quarters · filed 2025-05-12 | $801.00K derived: sum of 3 quarters · filed 2025-05-12 | $1.05M derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | $349.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | $570.00K derived: sum of 2 quarters · filed 2025-03-06 | $821.00K derived: sum of 3 quarters · filed 2025-03-06 | $1.02M 10-K · filed 2025-03-06 |
| 2023-09-30 | $221.00K 10-Q · filed 2024-11-07 | $472.00K derived: sum of 2 quarters · filed 2024-11-07 | $669.00K 10-Q · filed 2024-11-07 | $792.00K derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $251.00K 10-Q · filed 2024-08-07 | $448.00K 10-Q · filed 2024-08-07 | $571.00K derived: sum of 3 quarters · filed 2024-08-07 | -$3.26M derived: sum of 4 quarters · filed 2024-08-07 |
| 2023-03-31 | $197.00K 10-Q · filed 2024-05-14 | $320.00K derived: sum of 2 quarters · filed 2024-05-14 | -$3.51M derived: sum of 3 quarters · filed 2024-05-14 | -$3.39M derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | $123.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | -$3.71M derived: sum of 2 quarters · filed 2024-02-28 | -$3.59M derived: sum of 3 quarters · filed 2024-02-28 | -$3.59M 10-K · filed 2024-02-28 |
| 2022-09-30 | -$3.83M 10-Q · filed 2023-11-08 | -$3.71M derived: sum of 2 quarters · filed 2023-11-08 | -$3.71M 10-Q · filed 2023-11-08 | $387.00K derived: sum of 4 quarters · filed 2023-11-08 |
| 2022-06-30 | $120.00K 10-Q · filed 2023-08-08 | $120.00K 10-Q · filed 2023-08-08 | $4.22M derived: sum of 3 quarters · filed 2023-08-08 | $10.32M derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | $0.00 10-Q · filed 2023-05-08 | $4.10M derived: sum of 2 quarters · filed 2023-05-08 | $10.20M derived: sum of 3 quarters · filed 2023-05-08 | $17.40M derived: sum of 4 quarters · filed 2023-05-08 |
| 2021-12-31 | $4.10M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $10.20M derived: sum of 2 quarters · filed 2023-02-28 | $17.40M derived: sum of 3 quarters · filed 2023-02-28 | $17.40M 10-K · filed 2023-02-28 |
| 2021-09-30 | $6.10M 10-Q · filed 2022-11-07 | $13.30M derived: sum of 2 quarters · filed 2022-11-07 | $13.30M 10-Q · filed 2022-11-07 | |
| 2021-06-30 | $7.20M 10-Q · filed 2022-08-08 | $7.20M 10-Q · filed 2022-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 |